Predictive Oncology Inc. Announces Pricing of Public Offering of Up to $3,167,768.50 of Common Stock
October 02 2019 - 8:27AM
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive” or “the
Company”) today announced the pricing of its previously announced
public offering of its common stock, with anticipated gross
proceeds of up to $3,167,768.50, before deducting placement agent
fees and expenses and offering expenses payable by the Company. The
Company is offering 6,335,537 shares on a “best efforts” basis, at
a price of $0.50 per share. The offering is expected to close on or
about October 4, 2019, subject to customary closing conditions.
Dawson James Securities, Inc. and Paulson Investment Company,
LLC are acting as exclusive placement agents for the offering.
The offering is being made by Predictive pursuant to a shelf
registration statement previously filed with the Securities and
Exchange Commission (the “SEC”) and declared effective on October
4, 2016. The securities described above will be made only by means
of a prospectus supplement and accompanying prospectus. A
preliminary prospectus supplement and accompanying prospectus
related to the offering have been filed with the SEC and are
available on the SEC’s website located at http://www.sec.gov. A
final prospectus supplement and accompanying prospectus relating to
the offering will be filed with the SEC and will be available on
the SEC’s website at www.sec.gov. Copies of the final prospectus
supplement and accompanying prospectus relating to the offering,
when available, may also be obtained by contacting Dawson James
Securities, Inc., Attention: Prospectus Department, 1 North Federal
Highway, 5th Floor, Boca Raton, FL 33432, or by telephone toll free
at (866) 928-0928, or by email at mmaclaren@dawsonjames.com, or
Paulson Investment Company, LLC, 40 Wall Street, 23rd Floor, New
York, NY 10005 Attention: Marta Wypych at
mwypych@paulsoninvestment.com or by telephone at (646)
630-8891.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any jurisdiction in which such
offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
jurisdiction.
About Predictive Oncology Inc.
Predictive Oncology Inc. (NASDAQ: POAI) operates in two business
areas: first, applying artificial intelligence to personalized
medicine and drug discovery to provide personalized medicine
solutions for patients and clinicians as well as clients in the
pharmaceutical, diagnostic, and biotech industries, and second,
production of the FDA-approved STREAMWAY® System for automated,
direct-to-drain medical fluid disposal.
Forward-Looking Statements
This press release contains forward-looking statements,
including statements related to Predictive’s public offering of
common stock and warrants and the completion of the offering that
involve risks and uncertainties. These forward-looking statements
are based upon Predictive’s current expectations. Actual results
and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of risks
and uncertainties, which include, without limitation, risks and
uncertainties associated with market conditions and the
satisfaction of customary closing conditions related to the
proposed offering and other risks detailed in Predictive’s filings
with the Securities and Exchange Commission. You are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. All
forward-looking statements are qualified in their entirety by this
cautionary statement, and Predictive undertakes no obligation to
revise or update any forward-looking statements to reflect events
or circumstances after the date of this press release.
Bob Myers, Chief Financial
OfficerPredictive Oncology
Inc.Skyline Medical Inc.2915
Commers Drive, Suite 900Eagan, MN
55121Tel: 651-389-4806Fax:
651-389-4807
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Apr 2023 to Apr 2024